首页> 外文OA文献 >Erratum: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

【2h】

Erratum: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

机译：错误：勘误官：EGFR酪氨酸激酶抑制剂与化疗作为非小细胞肺癌患者的一线治疗L858R点突变

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jianlin Xu; Haitang Yang; Bo Jin; Yuqing Lou; Yanwei Zhang; Xueyan Zhang; Hua Zhong; Huiming Wang; Dan Wu; Baohui Han;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Hasegawa Yoshikazu, Ando Masahiko, Maemondo Makoto, The oncologist . 2015,第3期

机译：吸烟状态在非活化小细胞肺癌患者无进展生存中的作用，该患者具有接受一线EGFR酪氨酸激酶抑制剂与铂类双重治疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的荟萃分析。
2. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, The oncologist . 2015,第3期

机译：吸烟状态对非小细胞肺癌患者无进展生存的作用
3. Chemotherapy combined with Endostar as salvage treatment for EGFR-tyrosine kinase inhibitor primary resistance in an advanced non-small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report [J] . Dong Qiu, Yu Zhang, Ying-bo Xue, Thoracic cancer. . 2019,第4期

机译：化疗联合Endostar作为EGFR-Tyrosine激酶抑制剂初级抗性的矿物质治疗，高级非小细胞肺癌患者EGFR L858R突变和ROS1融合：案例报告
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. EGFR in Early Non-Small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial. [D] . Lara-Guerra, Humberto. 2011

机译：早期非小细胞肺癌中的EGFR：新辅助试验中酪氨酸激酶抑制作用。
6. Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation [O] . Jianlin Xu, Haitang Yang, Bo Jin, -1

机译：更正：EGFR酪氨酸激酶抑制剂与化学疗法作为具有L858R点突变的非小细胞肺癌患者的一线治疗
7. EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation [O] . Jianlin Xu, Haitang Yang, Bo Jin, 2016

机译：EGFR酪氨酸激酶抑制剂与化疗作为非小细胞肺癌患者的一线治疗L858R点突变

Erratum: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

著录项

引文网络

相似文献

相关主题

期刊订阅